High-performance electrophoresis systems engineered for RNA integrity analysis, capillary separation, and gel visualization — trusted by laboratories worldwide.
Capillary Electrophoresis (CE) for RNA analysis is an advanced separation technology that uses narrow-bore capillaries filled with a polymer sieving matrix to separate RNA molecules based on their size and charge-to-mass ratio. Unlike traditional slab gel electrophoresis, CE automates sample injection, migration, detection, and data output — delivering quantitative RNA size profiles with exceptional resolution and reproducibility.
The technique is especially critical for assessing RNA integrity — a key quality metric in transcriptomics, mRNA therapeutics, and diagnostics. The RNA Integrity Number (RIN) and DV200 score, both derived from CE-based analysis, have become gold-standard indicators accepted by regulatory agencies worldwide.
Modern CE systems for RNA integrate fluorescence detection, internal size standards, and software-driven analysis to generate detailed electropherograms — enabling researchers to make fast, data-driven decisions about sample quality before downstream experiments.
Capillary electrophoresis has penetrated every corner of RNA science — from basic research to regulated manufacturing environments.
CE is the cornerstone QC tool for mRNA drug products. Manufacturers use CE to verify mRNA length integrity, capping efficiency, and purity before release — critical for COVID-19 vaccines and next-gen mRNA medicines.
High-quality RNA is a prerequisite for reliable RNA-seq data. CE-based RIN scoring enables labs to screen thousands of samples rapidly, ensuring only intact RNA enters sequencing workflows.
CE enables sensitive detection of circulating RNA biomarkers (miRNA, lncRNA, cfRNA) in blood and urine — opening new frontiers in non-invasive cancer diagnostics and disease monitoring.
Degraded RNA from forensic samples or environmental specimens can be characterized using CE's DV200 metric, providing useful data even when RIN values are low — critical for FFPE tissue analysis.
GMP-grade CE systems provide batch-release testing and in-process control for RNA-based therapeutics, siRNA, antisense oligonucleotides, and gene therapy vectors at industrial scale.
A streamlined, automated workflow from sample to result in minutes.
RNA is extracted and optionally denatured. As little as 1–5 ng/μL is sufficient for modern CE systems.
Samples are electrokinetically injected into a polymer-filled capillary or microfluidic channel.
RNA fragments migrate through the sieving matrix under an electric field, separated by size.
Intercalating dyes or labeled probes enable sensitive detection of RNA bands at femtogram levels.
Software auto-generates electropherograms, calculates RIN/DV200, and produces gel-like images for comparison.
The global market for capillary electrophoresis in RNA analysis is expanding rapidly, driven by the mRNA therapeutics boom and increasing demand for high-throughput genomics workflows.
The success of mRNA COVID-19 vaccines has catalyzed massive investment in mRNA manufacturing infrastructure globally. CE has become a mandatory QC step in GMP mRNA production lines, driving adoption in pharmaceutical companies and CMOs worldwide.
Next-generation CE platforms integrate microfluidic chips that process 96 samples in parallel, reducing analysis time from hours to minutes. This miniaturization trend is opening CE to point-of-care and field-deployable RNA diagnostics.
Machine learning models trained on millions of CE runs can now automatically flag degraded samples, identify contamination signatures, and predict downstream assay success — reducing human error and accelerating data review.
Regulatory agencies (FDA, EMA, NMPA) are increasingly requiring CE-based RNA characterization data in IND and BLA submissions for RNA therapeutics, solidifying CE as an industry-standard analytical technique.
Traditional agarose gel electrophoresis has been the workhorse of RNA visualization for decades. However, as research and industry demands have escalated, its limitations — subjective band scoring, low throughput, large sample volume requirements, and poor quantification — have become critical bottlenecks.
Capillary electrophoresis addresses all these limitations. It offers automated, quantitative, and highly reproducible RNA analysis in a fraction of the time, with minimal sample consumption. The digital electropherogram replaces subjective gel band interpretation with objective numerical scores (RIN, DV200) that can be compared across runs, labs, and instruments.
For industrial applications where regulatory compliance and batch-to-batch consistency are paramount, CE's audit-trail capabilities, electronic data integrity features, and compatibility with 21 CFR Part 11 make it the clear choice.
Beijing Liuyi Biotechnology Co., Ltd., formerly known as Beijing Liuyi Instrument Factory, established in 1970, is a national high technology enterprise with a long history. It is a leading and the biggest manufacturer in electrophoresis instrument for life science laboratories in China.
Based on the life science and biotechnology industries, our main products always maintain a domestic industry-leading position and are well-known in the industry, exported to many countries and areas. We have our own R&D team, are open to scientific research innovation, prioritize market development, combine industry and research, and have achieved rapid economic growth for several years.
Liuyi has specialized in manufacturing electrophoresis instruments for more than 50 years with our own professional technical team and R&D center. We have a reliable and complete production line from design to inspection, and warehouse, as well as marketing support.
Our main products are Electrophoresis Cell (tank/chamber), Electrophoresis Power Supply, Blue LED Transilluminator, UV Transilluminator, Gel Image & Analysis System, and more. According to your requirements, we can provide customized services for you.
Liuyi has been awarded a variety of certificates and enterprise qualifications along with its high reputation in the industry. We are ISO 9001 & ISO 13485 certified company and some of our products have CE certificates. Since 2003, Liuyi as the only medical device manufacturer in Beijing medical industry has been awarded as "PROMISE-KEEPING ENTERPRISE" by Beijing Administration for Industry and Commerce.
In 2008, Liuyi is honored as the famous trademark of Beijing. Our trademark is under the protection of Madrid Protocol in 7 countries including the United States, the United Kingdom, Japan, South Korea, Singapore, Greece, and Zambia in 2005, as well we have registered our trademark in India and Vietnam.
Based on life science and biotechnology industry, with excellent reputation, we offer reliable quality products and good service to our customers in China and overseas. We are the key supplier for the government purchase projects, and we have nearly 2000 dealers in China. Our products have been exported to more than ten countries including America, Brazil, Mexico, India, Africa, Chile, Singapore etc. We are dedicated to offering our products throughout the world.
Beijing Liuyi Biotechnology Co., Ltd has launched new products for protein analysis, western blotting and gel observation. DYCZ-MINI series are fully compatible with the main international brands, and can run up to four precast or handcast polyacrylamide gels. The trans-blot module of DYCZ-TRANS2 is compatible with the chamber of DYCZ-MINI series. The WD-9403B can observe gel for nucleic acid electrophoresis. These new products are all durable, versatile, and easy to assemble. Welcome to contact us for more details!
Full-range electrophoresis accessories and systems designed to support every stage of your RNA analysis workflow — from sample separation to digital imaging and beyond.